Recognition of the potential of GLP-1 RAs to address obesity-related concerns, along with their potential for enhanced anti-inflammatory and neuroprotective effects, again indicates the importance of additional research on integration of this drug class into the perioperative care of neurosurgical patients. The gene discussed is GCG; the disease is obesity disorder.